News & Updates
Filter by Specialty:
Study throws light on vaccine hesitancy in Singapore
COVID-19 vaccine acceptance is high in Singapore, but there are still a reluctant few who prevent the nation from getting a higher immunization coverage against the infection.
Study throws light on vaccine hesitancy in Singapore
15 Jan 2022
High selenium concentrations may reduce death risk in diabetics
Greater concentrations of selenium appear to lower all-cause and heart disease mortality among individuals with type 2 diabetes (T2D), suggests a study.
High selenium concentrations may reduce death risk in diabetics
15 Jan 2022
Acute HF patients with diabetes derive less frailty benefit from physical rehab
Older diabetic patients with acute heart failure who undergo physical rehabilitation have worse baseline physical function but demonstrate similar clinically meaningful improvements from the intervention, results of the Rehabilitation Therapy in Older Acute Heart Failure Patients (REHAB-HF) trial have shown. However, the benefit derived for frailty is lesser among those with diabetes.
Acute HF patients with diabetes derive less frailty benefit from physical rehab
15 Jan 2022
High-dose radiotherapy boosts biochemical control in Gleason 9–10 prostate cancer
In patients with clinically localized Gleason 9–10 prostate cancer, dose-escalated radiotherapy confers better biochemical disease-free survival and prostate cancer-specific mortality than conventional doses, a recent study has found.
High-dose radiotherapy boosts biochemical control in Gleason 9–10 prostate cancer
15 Jan 2022
Cardiac rehabilitation improves short-term outcomes in HF patients
Cardiac rehabilitation is standard for the treatment of heart failure (HF) and yields short-term prognostic benefits, a recent study has found. However, long-term benefits remain uncertain.
Cardiac rehabilitation improves short-term outcomes in HF patients
15 Jan 2022
Pola-R-CHP triumphs over R-CHOP in improving PFS in DLBCL
The combination of polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) demonstrated a significant improvement in progression-free survival (PFS) over the standard-of-care (SoC) regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL), according to results of the phase III POLARIX study.